Asklepios BioPharmaceutical Inc. (AskBio) Revenue and Competitors

Location

$241.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Asklepios BioPharmaceutical Inc. (AskBio)'s estimated annual revenue is currently $114.6M per year.(i)
  • Asklepios BioPharmaceutical Inc. (AskBio)'s estimated revenue per employee is $217,000
  • Asklepios BioPharmaceutical Inc. (AskBio)'s total funding is $241.8M.

Employee Data

  • Asklepios BioPharmaceutical Inc. (AskBio) has 528 Employees.(i)
  • Asklepios BioPharmaceutical Inc. (AskBio) grew their employee count by 60% last year.

Asklepios BioPharmaceutical Inc. (AskBio)'s People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEO and Co-FounderReveal Email/Phone
3
Sr. VP, TherapeuticsReveal Email/Phone
4
VP Global Medical AffairsReveal Email/Phone
5
VP Manufacturing Science and TechnologyReveal Email/Phone
6
VP Translational MedicineReveal Email/Phone
7
VP, Therapeutic Sector LeaderReveal Email/Phone
8
SVP, Head People and CultureReveal Email/Phone
9
VP ITReveal Email/Phone
10
VP, ImmunologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is Asklepios BioPharmaceutical Inc. (AskBio)?

Asklepios BioPharmaceutical, Inc. (AskBio) was founded in 2001 by Richard Jude Samulski, PhD and Sheila Mikhail in Chapel Hill, NC to take advantage of the deep gene therapy resources in the Research Triangle Park area. AskBio has since set the standard for gene therapy clinical development including a deep portfolio of intellectual property in gene therapy for multiple diseases and an advanced manufacturing process.

keywords:N/A

$241.8M

Total Funding

528

Number of Employees

$114.6M

Revenue (est)

60%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Asklepios BioPharmaceutical Inc. (AskBio) News

2022-04-06 - Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer

She joins Spruce from Asklepios BioPharmaceutical (AskBio), where she served as Senior Vice President of Regulatory Affairs. Prior to AskBio...

2021-06-28 - AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

RESEARCH TRIANGLE PARK, N.C., June 28, 2021 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for the LION-101 gene therapy pr ...

2021-05-25 - AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA

RESEARCH TRIANGLE PARK, N.C., May 25, 2021 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that the U.S. Food & Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LION- ...

2021-05-06 - AskBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy's 24th Annual Meeting

RESEARCH TRIANGLE PARK, N.C., May 6, 2021 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that the Company will present abstracts and participate in sessions at the upcoming American Society of Gene & ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$566.7M292620%N/A